

Evaluation of the Cytotoxic, Antioxidative, and Antimicrobial Effects of *Dracocephalum moldavica* L. Cultivars

Ștefania Simea ¹, Irina Ielciu ^{2,*}, Daniela Hanganu ^{3,*}, Mihaela Niculae ⁴, Eموke Pall ⁴, Ramona Flavia Burtescu ⁵, Neli-Kinga Olah ^{5,6}, Mihai Cenariu ⁴, Ilioara Oniga ³, Daniela Benedec ³, and Marcel Duda ¹

¹ Department of Crop Science, Faculty of Agriculture, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania

² Department of Pharmaceutical Botany, Faculty of Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca, 400010 Cluj-Napoca, Romania

³ Department of Pharmacognosy, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Hațieganu”, 400000 Cluj-Napoca, Romania

⁴ Department of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400374 Cluj-Napoca, Romania

⁵ SC PlantExtrakt SRL, 407059 Rădaia, Cluj, Romania

⁶ Department of Therapeutical Chemistry, Pharmaceutical Industry and Biotechnologies, Faculty of Pharmacy, Vasile Goldiș Western University from Arad, 310048 Arad, Romania

* Correspondence: dhanganu@umfcluj.ro (D.H.); irina.ielciu@umfcluj.ro (I.I.)




Figure S1. LC-MS chromatograms obtained for the identification of caffeic acid in the A2 sample (3 injections).






Figure S2. LC-MS chromatograms obtained for the identification of chlorogenic acid in the A2 sample (3 injections).




Figure S3. LC-MS chromatograms obtained for the identification of carnosic acid in the A2 sample (3 injections).




Figure S4. LC-MS chromatograms obtained for the identification of trans-*p*-coumaric acid in the A2 sample (3 injections).




Figure S5. LC-MS chromatograms obtained for the identification of ellagic acid in the A2 sample (3 injections).






Figure S6. LC-MS chromatograms obtained for the identification of ferulic acid in the A2 sample (3 injections).






Figure S7. LC-MS chromatograms obtained for the identification of rosmarinic acid in the A2 sample (3 injections).






Figure S8. LC-MS chromatograms obtained for the identification of salicylic acid in the A2 sample (3 injections).



Figure S9. LC-MS chromatograms obtained for the identification of apigenin in the A2 sample (3 injections).






Figure S10. LC-MS chromatograms obtained for the identification of carnosol in the A2 sample (3 injections).





Figure S11. LC-MS chromatograms obtained for the identification of hyperoside in the A2 sample (3 injections).






Figure S12. LC-MS chromatograms obtained for the identification of luteolin in the A2 sample (3 injections).






Figure S13. LC-MS chromatograms obtained for the identification of luteolin-7-O-glucoside in the A2 sample (3 injections).




Figure S14. LC-MS chromatograms obtained for the identification of naringenin in the A2 sample (3 injections).




Figure S15. LC-MS chromatograms obtained for the identification of quercetin in the A2 sample (3 injections).






Figure S16. LC-MS chromatograms obtained for the identification of rutoside in the A2 sample (3 injections).






Figure S17. LC-MS chromatograms obtained for the identification of vitexin in the A2 sample (3 injections).

| A2 | A | Acontrol | I | I% | Conc (µg/mL) |
|----|--------|----------|----------|----------|--------------|
| 1 | 0,916 | 0,9719 | 0,057516 | 5,751621 | 6,25 |
| 2 | 0,813 | | 0,163494 | 16,34942 | 12,5 |
| 3 | 0,7352 | | 0,243544 | 24,35436 | 18,75 |
| 4 | 0,6314 | | 0,350345 | 35,03447 | 25 |
| 5 | 0,5465 | | 0,437699 | 43,76994 | 31,25 |
| 6 | 0,4557 | | 0,531125 | 53,11246 | 37,5 |
| 7 | 0,3679 | | 0,621463 | 62,14631 | 43,75 |
| 8 | 0,2804 | | 0,711493 | 71,1493 | 50 |




Figure S18. Determination of IC₅₀ for the A2 sample. Note: I % = (A control – A sample/A control) × 100 where A control is the absorbance of the control, composed of the DPPH• radical solution + methanol (mixture containing all reagents except the sample) and A sample is the absorbance of DPPH radical + sample. The DPPH radical scavenging activity of the sample was expressed as IC₅₀ (µg/mL), that is the concentration required to cause a 50% DPPH inhibition.

| B2 | A | Acontrol | I | I% | Conc (µg/mL) |
|----|--------|----------|----------|----------|--------------|
| 1 | 1,1161 | 1,1659 | 0,042714 | 4,271378 | 6,25 |
| 2 | 0,9737 | | 0,164851 | 16,48512 | 12,5 |
| 3 | 0,8729 | | 0,251308 | 25,1308 | 18,75 |
| 4 | 0,7782 | | 0,332533 | 33,25328 | 25 |
| 5 | 0,6667 | | 0,428167 | 42,81671 | 31,25 |
| 6 | 0,5549 | | 0,524059 | 52,40587 | 37,5 |
| 7 | 0,4253 | | 0,635217 | 63,52174 | 43,75 |
| 8 | 0,3374 | | 0,71061 | 71,06098 | 50 |




Figure S19. Determination of IC₅₀ for the B2 sample. Note: I % = (A control – A sample/A control) × 100 where A control is the absorbance of the control, composed of the DPPH• radical solution + methanol (mixture containing all reagents except the sample) and A sample is the absorbance of DPPH radical + sample. The DPPH radical scavenging activity of the sample was expressed as IC₅₀ (µg/mL), that is the concentration required to cause a 50% DPPH inhibition.

| A1 | A | Acontrol | I | I% | Conc (µg/mL) |
|----|--------|----------|----------|----------|--------------|
| 1 | 0,9857 | 1,5524 | 0,365048 | 36,50477 | 12,5 |
| 2 | 0,9045 | | 0,417354 | 41,73538 | 25 |
| 3 | 0,8345 | | 0,462445 | 46,24452 | 37,5 |
| 4 | 0,7246 | | 0,533239 | 53,32389 | 50 |
| 5 | 0,5742 | | 0,630121 | 63,01211 | 62,5 |
| 6 | 0,4826 | | 0,689127 | 68,91265 | 75 |
| 7 | 0,4012 | | 0,741561 | 74,15615 | 87,5 |
| 8 | 0,3321 | | 0,786073 | 78,60732 | 100 |




Figure S20. Determination of IC₅₀ for the A1 sample. Note: I % = (A control – A sample/A control) × 100 where A control is the absorbance of the control, composed of the DPPH• radical solution + methanol (mixture containing all reagents except the sample) and A sample is the absorbance of DPPH radical + sample. The DPPH radical scavenging activity of the sample was expressed as IC₅₀ (µg/mL), that is the concentration required to cause a 50% DPPH inhibition.

| Ascorbic acid | A | Acontrol | I | I% | Conc (µg/mL) |
|---------------|--------|----------|----------|----------|--------------|
| 1 | 1,2733 | 1,3793 | 0,076851 | 7,685058 | 1,25 |
| 2 | 1,0846 | | 0,213659 | 21,36591 | 2,5 |
| 3 | 0,9212 | | 0,332125 | 33,2125 | 3,75 |
| 4 | 0,7812 | | 0,433626 | 43,36258 | 5 |
| 5 | 0,6262 | | 0,546002 | 54,60016 | 6,25 |
| 6 | 0,4488 | | 0,674618 | 67,46176 | 7,5 |
| 7 | 0,305 | | 0,778873 | 77,88733 | 8,75 |
| 8 | 0,1443 | | 0,895382 | 89,53817 | 10 |




Figure S21. Determination of IC_{50} for the ascorbic acid. Note: $I\% = (A_{\text{control}} - A_{\text{sample}}/A_{\text{control}}) \times 100$ where A_{control} is the absorbance of the control, composed of the DPPH• radical solution + methanol (mixture containing all reagents except the sample) and A_{sample} is the absorbance of DPPH radical + sample. The DPPH radical scavenging activity of the sample was expressed as IC_{50} ($\mu\text{g/mL}$), that is the concentration required to cause a 50% DPPH inhibition.




Figure S22. *In vitro* antibacterial activity of the *D. moldavica* sample B2 by well diffusion method against reference strains: (a) *Staphylococcus aureus* ATCC 25923, (b) *Escherichia coli* ATCC 25922; positive (AMC, amoxicillin-clavulanic acid) and negative (70% Et-OH) control center placed; D-C (*D. moldavica* commercial product, data not included).




Figure S23. *In vitro* antibacterial activity of the *D. moldavica* samples (A1, A2, B2) as well as of the positive control (AMC, amoxicillin-clavulanic acid, center placed) by well diffusion method against *Pseudomonas aeruginosa* ATCC 27853, no inhibitory effect towards the reference strain.